Drug profile · INN
caplacizumab
CABLIVI
caplacizumab (CABLIVI) is a von willebrand factor inhibitor.
EMA: approved PMDA: approved Blood and blood forming organs (B01) B01A
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — caplacizumab
- Class
- Blood and blood forming organs (B01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
caplacizumab (CABLIVI) is a von willebrand factor inhibitor.
Key facts
INN caplacizumab
Brand CABLIVI
Mechanism von Willebrand factor inhibitor
Target von Willebrand factor
Therapeutic class Blood and blood forming organs (B01)
ATC code B01A
Mechanism of action
von Willebrand factor inhibitor
Primary target: von Willebrand factor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is caplacizumab?
caplacizumab (CABLIVI) is a von willebrand factor inhibitor.
What is the brand name for caplacizumab?
CABLIVI is a marketed brand name for caplacizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.